Home >> Life Sciences >> Pharmaceuticals

Mabion SA - Product Pipeline Review - 2015

Published: Jul-2015 | Format: PDF | Global Markets Direct | Number of pages: 27 | Code: MRS - 28516

Mabion SA - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Mabion SA - Product Pipeline Review - 2015’, provides an overview of the Mabion SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mabion SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mabion SA’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Mabion SA’s pipeline products

Reasons to buy

- Evaluate Mabion SA’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mabion SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mabion SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mabion SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mabion SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Mabion SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Mabion SA Snapshot 5
Mabion SA Overview 5
Key Information 5
Key Facts 5
Mabion SA - Research and Development Overview 6
Key Therapeutic Areas 6
Mabion SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Mabion SA - Pipeline Products Glance 11
Mabion SA - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Mabion SA - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Mabion SA - Drug Profiles 13
rituximab biosimilar 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
adalimumab biosimilar 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
bevacizumab biosimilar 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
cetuximab biosimilar 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ranibizumab biosimilar 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
trastuzumab biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Mabion SA - Pipeline Analysis 20
Mabion SA - Pipeline Products by Target 20
Mabion SA - Pipeline Products by Route of Administration 21
Mabion SA - Pipeline Products by Molecule Type 22
Mabion SA - Pipeline Products by Mechanism of Action 23
Mabion SA - Recent Pipeline Updates 24
Mabion SA - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27

List of Tables
Mabion SA, Key Information 5
Mabion SA, Key Facts 5
Mabion SA - Pipeline by Indication, 2015 7
Mabion SA - Pipeline by Stage of Development, 2015 9
Mabion SA - Monotherapy Products in Pipeline, 2015 10
Mabion SA - Phase III, 2015 11
Mabion SA - Preclinical, 2015 12
Mabion SA - Pipeline by Target, 2015 20
Mabion SA - Pipeline by Route of Administration, 2015 21
Mabion SA - Pipeline by Molecule Type, 2015 22
Mabion SA - Pipeline Products by Mechanism of Action, 2015 23
Mabion SA - Recent Pipeline Updates, 2015 24
Mabion SA, Other Locations 25

List of Figures
Mabion SA - Pipeline by Top 10 Indication, 2015 7
Mabion SA - Pipeline by Stage of Development, 2015 9
Mabion SA - Monotherapy Products in Pipeline, 2015 10
Mabion SA - Pipeline by Top 10 Target, 2015 20
Mabion SA - Pipeline by Top 10 Route of Administration, 2015 21
Mabion SA - Pipeline by Top 10 Molecule Type, 2015 22
Mabion SA - Pipeline Products by Top 10 Mechanism of Action, 2015 23

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Related Reports

North America and Europe Active Pharmaceutical Ingredients Market by Manufacturers, Regions, Type and Application, Forecast to 2023

Feb-2018 | Global Info Research | Pages : 103 | Code : MRS-216951 | 4480

This report studies the Active Pharmaceutical Ingredients market. An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical sub Read more

North America and Europe Botox Market by Manufacturers, Regions, Type and Application, Forecast to 2023

Feb-2018 | Global Info Research | Pages : 108 | Code : MRS-216950 | 4480

Botox is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species in the reproduction process. Botox is a polypeptide which molecular weight is 150kD and is also one of the most poisonous natural proteins. It is so easy to be produced, purified and refined due to its stable property that Botox is used widely in Experimental Research and Clinical Application at the early stage. Scope of the Report: This report focuses on the Botox in North America and Euro Read more

EMEA (Europe, Middle East and Africa) Vegetable Capsules Market 2017 Forecast to 2022

Jan-2018 | Global Info Research | Pages : 124 | Code : MRS-214954 | 4480

Pill is a common part of many people’s lives for pharmaceutical use or as health Supplements, It has two main forms of tablets and capsules. Tablets were the most popular way to take medicine for quite some time. While since some characters such as hard to swallow and slice, too many additives and so on, most people tend to switch to capsules from the industrialization era on when capsule shells technologies and filling machines have been developed. Scope of the Report: This report fo Read more

EMEA (Europe, Middle East and Africa) Sugar Sphere Market Professional Survey Market 2017 Forecast to 2022

Jan-2018 | Global Info Research | Pages : 121 | Code : MRS-214864 | 4480

Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere Market Professional Survey in EMEA market, covering Europe, Middle East and Africa, This report c Read more

Global Active Pharmaceutical Ingredients Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Feb-2018 | Global Info Research | Pages : 103 | Code : MRS-214050 | 3480

This report studies the Active Pharmaceutical Ingredients market. An active ingredient (AI) is the ingredient in a pharmaceutical drug that is biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active are also used in medicine, and the term active substance may be used for natural products. Some medication products may contain more than one active ingredient. The traditional word for the API is pharmacon or pharmakon which originally denoted a magical sub Read more

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Gene Synthesis Market 2018 Forecast to 2023

Feb-2018 | Global Info Research | Pages : 105 | Code : MRS-214049 | 4880

Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. Sco Read more

Global Botox Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Feb-2018 | Global Info Research | Pages : 108 | Code : MRS-214048 | 3480

Botox is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species in the reproduction process. Botox is a polypeptide which molecular weight is 150kD and is also one of the most poisonous natural proteins. It is so easy to be produced, purified and refined due to its stable property that Botox is used widely in Experimental Research and Clinical Application at the early stage. Scope of the Report: This report focuses on the Botox in global market, especia Read more

Global Pharmaceutical Hot Melt Extruder Market Research Report by Product Type, Application, Regions and Outlook 2017-2023

Jan-2018 | HeyReport | Pages : 77 | Code : MRS-213925 | 2030

Summary The global Pharmaceutical Hot Melt Extruder market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows: Read more

2018-2023 United States Neurofeedback System Market Report (Status and Outlook)

Feb-2018 | LPI (LP Information) | Pages : 89 | Code : MRS-213213 | 3360

In 2017, the Neurofeedback System market size was xx million in United States, and it will be xx million in 2023, with a CAGR of xx% between 2017 and 2023. In United States market, the top players include BrainMaster Technologies BEE Medic Brainquiry Mitsar Thought Technology Mind Media Wearable Sensing Split by product types/category, covering Slow Cortical Potential Neurofeedback (SCP-NF) Low-energy Neurofeedback System (LENS) Hemo Read more

2018-2023 UK Neurofeedback System Market Report (Status and Outlook)

Feb-2018 | LPI (LP Information) | Pages : 89 | Code : MRS-213212 | 3360

In 2017, the Neurofeedback System market size was xx million in UK, and it will be xx million in 2023, with a CAGR of xx% between 2017 and 2023. In UK market, the top players include BrainMaster Technologies BEE Medic Brainquiry Mitsar Thought Technology Mind Media Wearable Sensing Split by product types/category, covering Slow Cortical Potential Neurofeedback (SCP-NF) Low-energy Neurofeedback System (LENS) Hemoencephalographic (HEG) Read more

Single User | $(USD)1500 View Pricing